Active Ingredient: LETROZOLE; RIBOCICLIB SUCCINATE
Proprietary Name: KISQALI FEMARA CO-PACK (COPACKAGED)
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 2.5MG;EQ 200MG BASE
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N209935
Product Number: 001
Approval Date: May 4, 2017
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:
Prescription
Patent and Exclusivity Information